annual EBITDA:
$178.28M+$88.24M(+98.00%)Summary
- As of today (September 14, 2025), SUPN annual EBITDA is $178.28 million, with the most recent change of +$88.24 million (+98.00%) on December 31, 2024.
- During the last 3 years, SUPN annual EBITDA has risen by +$49.09 million (+38.00%).
- SUPN annual EBITDA is now -15.32% below its all-time high of $210.54 million, reached on December 31, 2020.
Performance
SUPN EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
$32.46M+$14.67M(+82.49%)Summary
- As of today (September 14, 2025), SUPN quarterly EBITDA is $32.46 million, with the most recent change of +$14.67 million (+82.49%) on June 30, 2025.
- Over the past year, SUPN quarterly EBITDA has dropped by -$6.46 million (-16.60%).
- SUPN quarterly EBITDA is now -49.65% below its all-time high of $64.47 million, reached on September 30, 2020.
Performance
SUPN quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
$148.57M-$6.46M(-4.17%)Summary
- As of today (September 14, 2025), SUPN TTM EBITDA is $148.57 million, with the most recent change of -$6.46 million (-4.17%) on June 30, 2025.
- Over the past year, SUPN TTM EBITDA has increased by +$22.94 million (+18.26%).
- SUPN TTM EBITDA is now -29.46% below its all-time high of $210.61 million, reached on March 31, 2021.
Performance
SUPN TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
SUPN EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +98.0% | -16.6% | +18.3% |
| 3 y3 years | +38.0% | -3.5% | +14.3% |
| 5 y5 years | +0.8% | -43.2% | -15.1% |
SUPN EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +98.0% | -45.8% | +730.0% | -4.8% | +64.0% |
| 5 y | 5-year | -15.3% | +98.0% | -49.6% | +730.0% | -29.5% | +64.0% |
| alltime | all time | -15.3% | +313.1% | -49.6% | +269.8% | -29.5% | +337.5% |
SUPN EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | $32.46M(+82.5%) | $148.57M(-4.2%) |
| Mar 2025 | - | $17.79M(-53.7%) | $155.03M(+0.8%) |
| Dec 2024 | $178.28M(+98.0%) | $38.41M(-35.9%) | $153.75M(-1.4%) |
| Sep 2024 | - | $59.92M(+53.9%) | $156.00M(+24.2%) |
| Jun 2024 | - | $38.92M(+135.9%) | $125.63M(+38.6%) |
| Mar 2024 | - | $16.50M(-59.4%) | $90.62M(-7.8%) |
| Dec 2023 | $90.04M(-41.3%) | $40.66M(+37.7%) | $98.25M(-11.4%) |
| Sep 2023 | - | $29.54M(+655.3%) | $110.91M(+8.6%) |
| Jun 2023 | - | $3.91M(-83.8%) | $102.11M(-22.6%) |
| Mar 2023 | - | $24.13M(-54.8%) | $131.84M(+0.1%) |
| Dec 2022 | $153.36M(+18.7%) | $53.33M(+157.2%) | $131.71M(+21.3%) |
| Sep 2022 | - | $20.74M(-38.4%) | $108.62M(-16.4%) |
| Jun 2022 | - | $33.65M(+40.2%) | $129.98M(+6.6%) |
| Mar 2022 | - | $23.99M(-20.7%) | $121.94M(-8.9%) |
| Dec 2021 | $129.19M(-38.6%) | $30.24M(-28.2%) | $133.79M(-14.6%) |
| Sep 2021 | - | $42.09M(+64.4%) | $156.73M(-12.5%) |
| Jun 2021 | - | $25.61M(-28.5%) | $179.11M(-15.0%) |
| Mar 2021 | - | $35.84M(-32.6%) | $210.61M(+2.0%) |
| Dec 2020 | $210.54M(+19.0%) | $53.19M(-17.5%) | $206.51M(+5.0%) |
| Sep 2020 | - | $64.47M(+12.9%) | $196.73M(+12.4%) |
| Jun 2020 | - | $57.11M(+80.0%) | $175.06M(+7.7%) |
| Mar 2020 | - | $31.73M(-26.9%) | $162.57M(+2.4%) |
| Dec 2019 | $176.85M(+7.0%) | $43.41M(+1.4%) | $158.82M(+1.2%) |
| Sep 2019 | - | $42.80M(-4.1%) | $156.96M(+2.2%) |
| Jun 2019 | - | $44.63M(+59.5%) | $153.52M(+4.9%) |
| Mar 2019 | - | $27.99M(-32.6%) | $146.39M(-3.4%) |
| Dec 2018 | $165.35M(+49.9%) | $41.55M(+5.6%) | $151.51M(+3.8%) |
| Sep 2018 | - | $39.36M(+5.0%) | $145.97M(+9.5%) |
| Jun 2018 | - | $37.50M(+13.3%) | $133.34M(+8.2%) |
| Mar 2018 | - | $33.10M(-8.1%) | $123.20M(+14.5%) |
| Dec 2017 | $110.32M | $36.01M(+34.8%) | $107.63M(+21.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2017 | - | $26.72M(-2.4%) | $88.58M(+7.6%) |
| Jun 2017 | - | $27.37M(+56.1%) | $82.30M(+22.3%) |
| Mar 2017 | - | $17.53M(+3.3%) | $67.27M(+18.8%) |
| Dec 2016 | $57.86M(+185.0%) | $16.97M(-17.0%) | $56.60M(+18.5%) |
| Sep 2016 | - | $20.44M(+65.7%) | $47.79M(+49.9%) |
| Jun 2016 | - | $12.33M(+79.6%) | $31.88M(+35.0%) |
| Mar 2016 | - | $6.87M(-15.8%) | $23.61M(+12.5%) |
| Dec 2015 | $20.30M(-641.9%) | $8.15M(+80.0%) | $20.99M(+17.9%) |
| Sep 2015 | - | $4.53M(+11.5%) | $17.79M(-58.3%) |
| Jun 2015 | - | $4.06M(-4.4%) | $42.67M(+0.2%) |
| Mar 2015 | - | $4.25M(-14.3%) | $42.60M(+69.3%) |
| Dec 2014 | -$3.75M(-95.5%) | $4.96M(-83.1%) | $25.16M(+177.7%) |
| Sep 2014 | - | $29.41M(+637.2%) | $9.06M(-124.3%) |
| Jun 2014 | - | $3.99M(-130.2%) | -$37.32M(-34.1%) |
| Mar 2014 | - | -$13.20M(+18.4%) | -$56.63M(-7.4%) |
| Dec 2013 | -$83.68M(+100.0%) | -$11.14M(-34.4%) | -$61.18M(-2.2%) |
| Sep 2013 | - | -$16.98M(+10.8%) | -$62.56M(+8.5%) |
| Jun 2013 | - | -$15.31M(-13.7%) | -$57.66M(+12.2%) |
| Mar 2013 | - | -$17.75M(+41.7%) | -$51.39M(+24.4%) |
| Dec 2012 | -$41.84M(+13.9%) | -$12.52M(+3.7%) | -$41.30M(+6.9%) |
| Sep 2012 | - | -$12.08M(+33.6%) | -$38.65M(+6.6%) |
| Jun 2012 | - | -$9.04M(+18.2%) | -$36.26M(+2.4%) |
| Mar 2012 | - | -$7.65M(-22.4%) | -$35.39M(-4.0%) |
| Dec 2011 | -$36.73M(-4.1%) | -$9.87M(+1.8%) | -$36.88M(-20.0%) |
| Sep 2011 | - | -$9.69M(+18.5%) | -$46.13M(+26.6%) |
| Jun 2011 | - | -$8.18M(-10.6%) | -$36.44M(+28.9%) |
| Mar 2011 | - | -$9.15M(-52.2%) | -$28.26M(+47.8%) |
| Dec 2010 | -$38.29M(-834.9%) | -$19.12M(+42.3%) | -$19.12M(+42.3%) |
| Dec 2009 | $5.21M(-122.0%) | -$13.44M | -$13.44M |
| Dec 2008 | -$23.69M(+45.0%) | - | - |
| Dec 2007 | -$16.34M | - | - |
FAQ
- What is Supernus Pharmaceuticals, Inc. annual EBITDA?
- What is the all time high annual EBITDA for Supernus Pharmaceuticals, Inc.?
- What is Supernus Pharmaceuticals, Inc. annual EBITDA year-on-year change?
- What is Supernus Pharmaceuticals, Inc. quarterly EBITDA?
- What is the all time high quarterly EBITDA for Supernus Pharmaceuticals, Inc.?
- What is Supernus Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
- What is Supernus Pharmaceuticals, Inc. TTM EBITDA?
- What is the all time high TTM EBITDA for Supernus Pharmaceuticals, Inc.?
- What is Supernus Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
What is Supernus Pharmaceuticals, Inc. annual EBITDA?
The current annual EBITDA of SUPN is $178.28M
What is the all time high annual EBITDA for Supernus Pharmaceuticals, Inc.?
Supernus Pharmaceuticals, Inc. all-time high annual EBITDA is $210.54M
What is Supernus Pharmaceuticals, Inc. annual EBITDA year-on-year change?
Over the past year, SUPN annual EBITDA has changed by +$88.24M (+98.00%)
What is Supernus Pharmaceuticals, Inc. quarterly EBITDA?
The current quarterly EBITDA of SUPN is $32.46M
What is the all time high quarterly EBITDA for Supernus Pharmaceuticals, Inc.?
Supernus Pharmaceuticals, Inc. all-time high quarterly EBITDA is $64.47M
What is Supernus Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
Over the past year, SUPN quarterly EBITDA has changed by -$6.46M (-16.60%)
What is Supernus Pharmaceuticals, Inc. TTM EBITDA?
The current TTM EBITDA of SUPN is $148.57M
What is the all time high TTM EBITDA for Supernus Pharmaceuticals, Inc.?
Supernus Pharmaceuticals, Inc. all-time high TTM EBITDA is $210.61M
What is Supernus Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
Over the past year, SUPN TTM EBITDA has changed by +$22.94M (+18.26%)